Serotonin modulates the mitogenic MAPK/ERK and PI3K/Akt signaling pathways in prostate cancer, and stimulates phosphorylation of ERK1/2 through the MAPK pathway in the PC3 prostate cancer cell line (Figure 4). Here, AKT1 is linked to prostate carcinoma.